Victor L. Serebruany
Novartis
163 Papers
1.5K Citations
Victor L. Serebruany is an academic researcher from Novartis. The author has contributed to research in topics: Clopidogrel & Platelet activation. The author has an hindex of 31, co-authored 156 publications. Previous affiliations of Victor L. Serebruany include Durham University & University of Maryland, Baltimore.
Chat about Author
Papers
Clopidogrel response variability: impact of genetic polymorphism and platelet biomarkers for predicting adverse outcomes poststenting.
Elena Z. Golukhova,Mariya N. Ryabinina,Naida I. Bulaeva,Marina V. Grigorian,Maida Ch. Kubova,Victor L. Serebruany +5 more
TL;DR: Platelet reactivity is higher in patients with heterozygous and homozygous carriers of CYP2C19*2 versus common genotype and may predict an increased risk of clopidogrel response variability and/or experiencing adverse cardiac events.
Time Course of Degradation of Cardiac Troponin I in Patients With Acute ST-Elevation Myocardial Infarction The ASSENT-2 Troponin Substudy
Lene Helleskov Madsen,Lene Helleskov Madsen,Geir Christensen,Terje Lund,Victor L. Serebruany,Christopher B. Granger,Ingvild B Hoen,Zanina Grieg,John H. Alexander,Allan S. Jaffe,Jennifer E. Van Eyk,Dan Atar +11 more
TL;DR: Intact cTnI and a single degradation product were detectable on immunoblot as early as 90 minutes after onset of symptoms with further degradation after 165 minutes, defining for the first time the initial time course of cardiac troponin I degradation in STEMI.
Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials.
Victor L. Serebruany,Steven R. Steinhubl,Peter B. Berger,Alex I. Malinin,Jeffrey S. Baggish,Deepak L. Bhatt,Eric J. Topol +6 more
TL;DR: Findings should be considered when using combination antiplatelets, anticoagulant therapy, or both, with ASA, especially with the daily dose of >100 mg, despite substantial differences in the reporting patterns of bleeding complications.
Bleeding risks with prasugrel in the TRITON trial: good news ... bad news.
TL;DR: Analysis of the evidence reveals some good news and bad news concerning the potential clinical utility of the experimental thienopyridine, and therapy with prasugrel is associated with lower bleeding risks than those reported historically with oral glycoprotein IIb/IIIa inhibitors.
The FDA Prasugrel Review: Adjudication of Myocardial Infarction Controversy
TL;DR: An optimistic interpretation of the TRITON results is clouded by the several changes of MI definition during prasugrel development, including one change adopted during the trial, which resulted in an extraordinarily high MI rate in the clopidogrel arm for a population such as that employed in the trial.